Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patients.
Kakkos A, Bresson L, Hudry D, Cousin S, Lervat C, Bogart E, Meurant JP, El Bedoui S, Decanter G, Hannebicque K, Regis C, Hamdani A, Penel N, Tresch-Bruneel E, Narducci F. Kakkos A, et al. Eur J Surg Oncol. 2017 Apr;43(4):689-695. doi: 10.1016/j.ejso.2016.10.020. Epub 2016 Nov 5. Eur J Surg Oncol. 2017. PMID: 27889197
Pretherapeutic staging of locally advanced cervical cancer: Inframesenteric paraaortic lymphadenectomy accuracy to detect paraaortic metastases in comparison with infrarenal paraaortic lymphadenectomy.
Azaïs H, Ghesquière L, Petitnicolas C, Borghesi Y, Tresch-Bruneel E, Cordoba A, Narducci F, Bresson L, Leblanc E. Azaïs H, et al. Among authors: tresch bruneel e. Gynecol Oncol. 2017 Nov;147(2):340-344. doi: 10.1016/j.ygyno.2017.09.012. Epub 2017 Sep 14. Gynecol Oncol. 2017. PMID: 28919265
REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.
Berry V, Basson L, Bogart E, Mir O, Blay JY, Italiano A, Bertucci F, Chevreau C, Clisant-Delaine S, Liegl-Antzager B, Tresch-Bruneel E, Wallet J, Taieb S, Decoupigny E, Le Cesne A, Brodowicz T, Penel N. Berry V, et al. Among authors: tresch bruneel e. Cancer. 2017 Jun 15;123(12):2294-2302. doi: 10.1002/cncr.30661. Epub 2017 Mar 10. Cancer. 2017. PMID: 28295221 Free PMC article. Clinical Trial.
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
Bompas E, Le Cesne A, Tresch-Bruneel E, Lebellec L, Laurence V, Collard O, Saada-Bouzid E, Isambert N, Blay JY, Amela EY, Salas S, Chevreau C, Bertucci F, Italiano A, Clisant S, Penel N. Bompas E, et al. Ann Oncol. 2015 Oct;26(10):2168-73. doi: 10.1093/annonc/mdv300. Epub 2015 Jul 22. Ann Oncol. 2015. PMID: 26202596 Free PMC article. Clinical Trial.
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.
Lebellec L, Bertucci F, Tresch-Bruneel E, Ray-Coquard I, Le Cesne A, Bompas E, Blay JY, Italiano A, Mir O, Ryckewaert T, Toiron Y, Camoin L, Goncalves A, Penel N, Le Deley MC. Lebellec L, et al. Among authors: tresch bruneel e. BMC Cancer. 2018 Oct 11;18(1):963. doi: 10.1186/s12885-018-4828-1. BMC Cancer. 2018. PMID: 30305054 Free PMC article. Clinical Trial.
Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.
Ray-Coquard IL, Domont J, Tresch-Bruneel E, Bompas E, Cassier PA, Mir O, Piperno-Neumann S, Italiano A, Chevreau C, Cupissol D, Bertucci F, Bay JO, Collard O, Saada-Bouzid E, Isambert N, Delcambre C, Clisant S, Le Cesne A, Blay JY, Penel N. Ray-Coquard IL, et al. J Clin Oncol. 2015 Sep 1;33(25):2797-802. doi: 10.1200/JCO.2015.60.8505. Epub 2015 Jul 27. J Clin Oncol. 2015. PMID: 26215950 Clinical Trial.
19 results